The U.S. National Institutes of Health's National Eye Institute is spending up to $17.9 million over the next 5 years to find new therapies for blindness. In addition, the NIH just unveiled its Alzheimer's disease research agenda.
Legislation that would mandate the creation of a system to share de-identified clinical trial data has moved a step closer to coming into force. The text is included in the latest draft of the 21st Century Cures Act, which is almost 200 pages shorter than the original proposal.
Sterilucent has raised almost $4 million just about 6 months after the FDA cleared its Sterilucent PSD-85 Hydrogen Peroxide Sterilizer for use in healthcare facilities with tough surroundings such as combat hospitals and disaster response sites.
The U.S. National Institutes of Health is funneling more than $11 million toward 9 research programs developing rapid diagnostics for antimicrobial resistance, a week after the Obama administration announced a plan to prioritize point-of-care testing to curtail the rise of drug-resistant bacteria.
In a win for HIV vaccine research, Duke University researchers have scored $20 million in grants from the National Institutes of Health to develop an HIV vaccine.
The millimeters-wide opening of the inner ear has long stymied efforts at drug delivery, but progress is being made, according to Scientific American. Draper Lab is working to create a small intracochlear device designed to treat hearing loss.
Only 13% of clinical trials registered at ClinicalTrials.gov posted their results within one year of data collection, as required by federal law, according to a study in The New England Journal of Medicine.
The National Institutes of Health (NIH) has put the establishment of a way to combine data from different sources at the top of its list of initial priorities for President Obama's precision medicine initiative. Such a system is essential if the NIH is to pull off its plan of making use of data generated by third parties.
In bid to improve patient adherence, the U.S. National Institutes of Health is funding and helping run two clinical trials of long-acting injectable HIV candidates being developed by Johnson & Johnson's Janssen and GlaxoSmithKline.
The National Center for Complementary and Integrative Health at the National Institutes of Health (NIH) has proposed conducting large research studies of nondrug pain management approaches. It did so in a report by a working group of the Center's Advisory Council.